Research Fund of Basic Research Project of Shenzhen(Natural Science Foundation of Shenzhen),No.JCYJ20230807142205010.
BACKGROUND Hepatoid adenocarcinoma of the lung(HAL)is a rare type of non-small cell lung cancer(NSCLC),histologically similar to hepatocellular carcinoma.HAL has high malignancy and poor prognosis,and a better treatme...
BACKGROUND With advancements in the diagnosis and treatment of lung diseases,lung segment surgery has become increasingly common.Postoperative rehabilitation is critical for patient recovery,yet challenges such as com...
BACKGROUND The extensive availability of ultrasound(US)technology has increased its use for point-of-care applications in many health care settings.During anaesthesia and surgery,acute respiratory failure or pulmonary...
BACKGROUND Mucoepidermoid carcinoma of the lung is a rare malignant tumor,accounting for 0.1%–0.2%of all lung malignancies.It is a primary salivary gland tumor of the lung.Surgical resection is the primary treatment ...
BACKGROUND Lung endometriosis is an extremely rare gynecological disease.Current literature reports suggest that the majority of patients will present with only generic symptoms,such as hemoptysis,pneumothorax,and hem...
BACKGROUND Primary dedifferentiated chondrosarcoma(DDCS)of the lung is extremely rare and has a poor prognosis,especially in patients with a history of carcinomas and related treatment.Herein,we report a case of prima...
Supported by the Science and Technology Research Project of Sichuan Provincial Administration of Traditional Chinese Medicine,No.2021MS164;Scientific research project of Sichuan Medical Association,No.S21012。
BACKGROUND Lung invasive mucinous adenocarcinoma(LIMA),formerly referred to as mucinous bronchioloalveolar carcinoma,is a rare disease that usually presents as bilateral lung infiltration,is unsuitable for surgery and...
BACKGROUND Hepatoid adenocarcinoma of the lung(HAL) is an extremely rare malignant tumor,and many patients with HAL exhibit high levels of alpha-fetoprotein(AFP) expression.Currently,there is no standardized treatment...
BACKGROUND For advanced lung squamous cell carcinoma,immune checkpoint inhibitors(ICIs)have been regarded as one of the optimal therapies.While immune-related adverse events(ir AEs)are common in ICI treatment,cutaneou...